Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Blood (2022) 140 (Supplement 1): 6847–6849.

https://doi.org/10.1182/blood-2022-156632

Published: 2022

Journal Articles

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Blood (2017) 130 (Supplement 1): 323.

https://doi.org/10.1182/blood.V130.Suppl_1.323.323

Published: 2017

Journal Articles

Nationwide Survey on the Use of Eltrombopag in Patients with Severe Aplastic Anemia: Report on Behalf of the French Reference Center for Aplastic Anemia

Blood (2016) 128 (22): 2684.

https://doi.org/10.1182/blood.V128.22.2684.2684

Published: 2016

Journal Articles

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Blood (2016) 128 (22): 3128.

https://doi.org/10.1182/blood.V128.22.3128.3128

Published: 2016

Journal Articles

AML At First Relapse: A Real Life Picture

Eileen Mary Boyle, MD, Claude Preudhomme, MD, PhD, Olivier Nibourel, Catherine Roche-Lestienne, PhD, Gareth J Morgan, MD PhD, Brigitte Dupriez, MD, Isabelle Plantier, MD, Berengere Gruson, MD, Jean Pierre Marolleau, MD, PhD, Delphine Lebon, MD, Jose Fernandes, MD, Christophe Willekens, Bruno Quesnel, MD, PhD, Céline Berthon, MD, PhD

Blood (2013) 122 (21): 3895.

https://doi.org/10.1182/blood.V122.21.3895.3895

Published: 2013

Journal Articles

Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc

Marie Robin, MD, PhD, Sylvie Francois, MD, Anne Huynh, Bruno Cassinat, PharmD, PhD, Jacques-Olivier Bay, MD, PhD, Jérôme Cornillon, MD, Valerie Rolland, Amandine Charbonnier, MD, Mauricette Michallet, MD, PhD, Françoise Boyer, Stephane Vigouroux, MD, Laure Vincent, MD, Ibrahim Yakoub-Agha, MD, PhD, Raphael Porcher, PhD, Gérard Socié, MD, PhD, Brigitte Dupriez, MD, Jean-Jacques Kiladjian, MD, PhD

Blood (2013) 122 (21): 306.

https://doi.org/10.1182/blood.V122.21.306.306

Published: 2013

Journal Articles

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

Ayalew Tefferi, Francisco Cervantes, Ruben Mesa, Francesco Passamonti, Srdan Verstovsek, Alessandro M. Vannucchi, Jason Gotlib, Brigitte Dupriez, Animesh Pardanani, Claire Harrison, Ronald Hoffman, Heinz Gisslinger, Nicolaus Kröger, Juergen Thiele, Tiziano Barbui, Giovanni Barosi

Blood (2013) 122 (8): 1395–1398.

https://doi.org/10.1182/blood-2013-03-488098

Published: 2013

Includes: Supplemental data

Journal Articles

Impairment of Myeloid Dendritic Differentiation and Role in the Support of Splenic Dysmegakaryopoiesis in Patients with Primary Myelofibrosis

Christophe Desterke, PhD, Bernadette Guerton, Sophie Amsellem, PhD, Agnes Charpentier, MD, Brigitte Dupriez, MD, Jean-Loup Demory, MD, Christophe Martinaud, MD, Jean-Jacques Lataillade, Julien Giron-Michel, Bruno Azzarone, Marie-Caroline Le Bousse-Kerdiles, PhD

Blood (2012) 120 (21): 1762.

https://doi.org/10.1182/blood.V120.21.1762.1762

Published: 2012

Journal Articles

Ruxolitinib Therapy in Myelofibrosis: Analysis of 241 Patients Treated in Compassionate Use (French “ATU” program) by the French Intergroup of Myeloproliferative Neoplasms (FIM).

Blood (2012) 120 (21): 2841.

https://doi.org/10.1182/blood.V120.21.2841.2841

Published: 2012

Journal Articles

The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,

Christophe Desterke, PhD, Costanza Bogani, PhD, Lisa Pieri, MD, Alessandro M. Vannucchi, MD, PhD, Bernadette Guerton, Christophe Martinaud, MD, Denis Clay, Jean-Jacques Lataillade, MD, PhD, Hans Hasselbalch, MD, PhD, Heinz Gisslinger, MD, PhD, Sophie Amsellem, PhD, Jean-Loup Demory, MD, Agnès Charpentier, MD, Brigitte Dupriez, Claude Boucheix, MD, PhD, Eric Rubinstein, PhD, Marie-Caroline Le Bousse-Kerdiles, PhD

Blood (2011) 118 (21): 3834.

https://doi.org/10.1182/blood.V118.21.3834.3834

Published: 2011

Journal Articles

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

Blood (2011) 118 (21): 6.

https://doi.org/10.1182/blood.V118.21.6.6

Published: 2011

Journal Articles

Efficacy and Safety of Peg-Interferon-α2a In Myelofibrosis: a Study of the FIM and GEM French Cooperative Groups

Jean-Christophe Ianotto, Françoise Boyer-Perrard, Jean-Loup Demory, MD, Jerome Rey, Lydia Roy, MD, Christian Berthou, Brigitte Dupriez, MD, Dana Ranta, Mireille Potard, Michele Schoenwald, Jean-François Abgrall, Jean-Jacques Kiladjian, MD, PhD

Blood (2010) 116 (21): 4103.

https://doi.org/10.1182/blood.V116.21.4103.4103

Published: 2010

Journal Articles

Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients

Pierre Morel, Alain Duhamel, Benedicte Hivert, Laure Stalniekiewicz, Jean-Loup Demory, Brigitte Dupriez

Blood (2010) 115 (22): 4350–4355.

https://doi.org/10.1182/blood-2009-12-255943

Published: 2010

Includes: Supplemental data

Journal Articles

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

Francisco Cervantes, Brigitte Dupriez, Arturo Pereira, Francesco Passamonti, John T. Reilly, Enrica Morra, Alessandro M. Vannucchi, Ruben A. Mesa, Jean-Loup Demory, Giovanni Barosi, Elisa Rumi, Ayalew Tefferi

Blood (2009) 113 (13): 2895–2901.

https://doi.org/10.1182/blood-2008-07-170449

Published: 2009

Includes: Supplemental data

Journal Articles

A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment

Francisco Cervantes, MD, Brigitte Dupriez, MD, Arturo Pereira, MD, Francesco Passamonti, MD, John T Reilly, MD, Enrica Morra, MD, Alessandro Vannucchi, MD, Ruben A. Mesa, MD, FACP, Jean-Loup Demory, MD, Giovanni Barosi, MD, Elisa Rumi, MD, Ayalew Tefferi, MD

Blood (2008) 112 (11): 657.

https://doi.org/10.1182/blood.V112.11.657.657

Published: 2008

Journal Articles

Clinical Evolution to Primary Myelofibrosis - Blast Phase: An International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Collaborative Retrospective Analysis.

Ruben A. Mesa, MD, Francisco Cervantes, MD, Srdan Verstovsek, MD, PhD, Constantine Tam, MD, Brigitte Dupriez, MD, John Reilly, MD, Giovanni Barosi, MD, Megan Campbell, MS, Wenting Wu, PhD, A. Pardanani, MD, PhD, T. Lasho, Ayalew Tefferi, MD

Blood (2007) 110 (11): 682.

https://doi.org/10.1182/blood.V110.11.682.682

Published: 2007

Journal Articles

Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). Results of a Multicentric Phase II Study.

Carole Soussain, MD, Khe Hoang-Xuan, MD, Luc Taillandier, MD, Olivier Casasnovas, MD, Brigitte Dupriez, MD, Anne-Laure Taksin, MD, Bertrand Souleau, MD, Brigitte Kolb, MD, Arnaud Jaccard, MD, Jean-Marc Zini, MD, Sylvain Choquet, MD, Francis Witz, MD, Maud Janvier, MD, Veronique Leblond, MD

Blood (2006) 108 (11): 402.

https://doi.org/10.1182/blood.V108.11.402.402

Published: 2006

Journal Articles

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)

Blood (2006) 108 (5): 1497–1503.

https://doi.org/10.1182/blood-2006-03-009746

Published: 2006

Journal Articles

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

Blood (2006) 107 (5): 2098–2100.

https://doi.org/10.1182/blood-2005-08-3395

Published: 2006

Journal Articles

Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)

Giovanni Barosi, Dominique Bordessoule, Jean Briere, Francisco Cervantes, Jean-Loup Demory, Brigitte Dupriez, Heinz Gisslinger, Martin Griesshammer, Hans Hasselbalch, Rajko Kusec, Marie-Caroline Le Bousse-Kerdiles, Nicola L. Liberato, Monia Marchetti, John T. Reilly, Jurgen Thiele

Blood (2005) 106 (8): 2849–2853.

https://doi.org/10.1182/blood-2005-04-1520

Published: 2005

NARROW

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Nationwide Survey on the Use of Eltrombopag in Patients with Severe Aplastic Anemia: Report on Behalf of the French Reference Center for Aplastic Anemia

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

AML At First Relapse: A Real Life Picture

Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

Impairment of Myeloid Dendritic Differentiation and Role in the Support of Splenic Dysmegakaryopoiesis in Patients with Primary Myelofibrosis

Ruxolitinib Therapy in Myelofibrosis: Analysis of 241 Patients Treated in Compassionate Use (French “ATU” program) by the French Intergroup of Myeloproliferative Neoplasms (FIM).

The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

Efficacy and Safety of Peg-Interferon-α2a In Myelofibrosis: a Study of the FIM and GEM French Cooperative Groups

Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment

Clinical Evolution to Primary Myelofibrosis - Blast Phase: An International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Collaborative Retrospective Analysis.

Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). Results of a Multicentric Phase II Study.

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only